Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases.

Our vision is to make precision medicine available to physicians and patients for the treatment of cancers and other difficult-to-treat diseases.

We are working to provide clinicians with an accurate and improved way to select the patients who may receive the greatest benefit from a particular therapy. Because our values are founded on improving the health of patients, we strive to achieve targeted drug delivery to diseased cells to improve effectiveness of therapy and reduce undesirable side effects.

West Lafayette, US
Size (employees)
76 (est)-2%
Endocyte was founded in 1995 and is headquartered in West Lafayette, US

Key People at Endocyte

Mike A. Sherman

Mike A. Sherman


Endocyte Office Locations

Endocyte has an office in West Lafayette
West Lafayette, US (HQ)
3000 Kent Avenue

Endocyte Data and Metrics

Endocyte Financial Metrics

Endocyte's revenue was reported to be $70 k in FY, 2016
Numbers are in $, USD

Revenue (FY, 2016)

70 k

Net income (FY, 2016)

(43.9 m)

EBIT (FY, 2016)

(44.7 m)

Market capitalization (26-May-2017)

104.9 m

Closing share price (26-May-2017)


Cash (31-Dec-2016)

31.2 m
Endocyte's current market capitalization is $104.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


64.9 m70.4 m70 k70 k

Revenue growth, %


Operating expense total

83.2 m65.3 m42 m44.8 m


(18.3 m)5 m(42 m)(44.7 m)

EBIT margin, %


Interest expense

2.5 k1.2 k

Interest income

465.5 k578.6 k

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


52.8 m45.5 m15.4 m31.2 m

Accounts Receivable


Current Assets

133.3 m127 m174.9 m140.3 m


3.8 m4 m3.4 m3.2 m

Total Assets

162.9 m212.8 m178.4 m143.5 m

Accounts Payable

5.4 m1.2 m1.3 m1.4 m

Current Liabilities

73.7 m6.9 m6.2 m5.6 m

Additional Paid-in Capital

262.1 m373.6 m381.1 m390.8 m

Retained Earnings

(173.9 m)(168.5 m)(209.7 m)(253.6 m)

Total Equity

205 m171.3 m137.1 m

Financial Leverage

1 x1 x1 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)

Depreciation and Amortization

674.7 k857.1 k886.7 k

Accounts Receivable


Accounts Payable

(386.2 k)(3.7 m)(60.7 k)1.4 m

Cash From Operating Activities

(51.1 m)(42.2 m)(32.2 m)

Purchases of PP&E

(827.8 k)(1.5 m)(341.6 k)

Cash From Investing Activities

69.3 m(68.6 m)1.5 m

Cash From Financing Activities

644.9 k103.5 m627 k
Numbers are in $, USDY, 2016



Financial Leverage

1 x

Endocyte Market Value History

Endocyte Company Life and Culture

You may also be interested in